Thermo Fisher Scientific Invests $25 Million to Support Black Communities and Businesses in the U.S.
Thermo Fisher Scientific Inc. the world leader in serving science, today announced it has committed to investing up to $25 million in minority-serving financial institutions. “Unequal access to capital is hurting Black-owned businesses, Black entrepreneurs and Black communities in the United States ,” said Marc N. Casper chairman, president and chief executive officer of Thermo Fisher Scientific. “Minority-serving …
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has committed to investing up to $25 million in minority-serving financial institutions. “Unequal access to capital is hurting Black-owned businesses, Black entrepreneurs and Black communities in the United States ,” said Marc N. Casper , chairman, president and chief executive officer of Thermo Fisher Scientific. “Minority-serving financial institutions
Mycolicibacter kumamotonensis, a pathogen that was described in 2006 (
Figure
Figure. Chest computed tomography scan 1 month after antituberculosis treatment initiation (A–C), at the time of
Mycolicibacter kumamotonensis identification (D–F), and 1 year after treatment initiation for .
A 68-year-old woman in Greece had had shortness of breath, productive cough, and low-grade fever for several weeks. The patient was from Georgia but had been living in Greece for the preceding 20 years; she had a history of breast cancer, which had been treated with chemotherapy and radiotherapy 7 years earlier, and bronchiectasis. During the preceding 3 years, the patient had recurrent chest infections and received multiple antimicrobial drug regimens. Based on a positive sputum acid-fast staining, standard antituberculosis treatment was initiated. Culture of the sputum sample was macroscopically suggestive of nontuberculous mycobacteria, but identification of the species was not feasible bec
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Thermo Fisher Scientific Partners with Mindray on Clinical Chemistry Analyzers for use with Drugs of Abuse Immunoassays
February 9, 2021 GMT
Thermo Fisher Scientific (PRNewsfoto/Thermo Fisher Scientific)
FREMONT, Calif., Feb. 9, 2021 /PRNewswire/ Thermo Fisher Scientific, the world leader in serving science, today announced a partnership with Mindray, a leading global developer, manufacturer and supplier of medical devices, to make available to customers two clinical chemistry analyzers in the United States (U.S.) and Canada for drug screening in clinical and drug court laboratories.
“Systematically and reliably testing for drugs of abuse is key to helping addicted individuals rehabilitate, ensuring prescribed drugs are not abused and ultimately, helping to combat this crisis,” said Stefan Wolf, president of the clinical diagnostics business at Thermo Fisher Scientific. “Through t
Share this article
Share this article
CARLSBAD, Calif., Feb. 8, 2021 /PRNewswire/ Thermo Fisher Scientific, the world leader in serving science, today launched its CE-IVD-Marked, Applied Biosystems TaqPath COVID–19 HT Kit that is compatible with the Amplitude platform. The high-throughput solution enables clinical and public health laboratories to efficiently test up to 8,000 COVID-19 samples a day with fewer staffing requirements and a reliable supply of kits, reagents and consumables.
The highly automated Amplitude platform is a molecular diagnostic system that allows labs to increase their COVID-19 testing capacity by combining Thermo Fisher s extraction and real-time PCR instruments with liquid handling products from Tecan Group. The system leverages a high-throughput version of Thermo Fisher s TaqPath COVID-19 CE-IVD RT-PCR Kit, which received CE-IVD Mark in March 2020.
Share this article
Share this article
WALTHAM, Mass., Feb. 3, 2021 /PRNewswire/ Thermo Fisher Scientific, the world leader in serving science, has signed an agreement with JW Therapeutics, a leading cell therapy company, to ensure non-exclusive commercial access to Thermo Fisher s Gibco CTS Dynabeads CD3/CD28.
The agreement will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW Therapeutics lead product relmacabtagene autoleucel ( relma-cel ). Relma-cel is an anti-CD19 CAR-T therapy for third-line treatment for relapsed or refractory ( r/r ) B-cell lymphoma. The therapy s new drug application (NDA) has been accepted by China s National Medical Products Administration (NMPA). Relma-cel is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China.